|
|


Haemonetics Corporation and Subsidiaries
Five-Year GAAP Review
(in thousands, except share and employee data)
| Summary of Operations |
2009 |
2008 |
2007 |
2006 (a) |
2005 (a) |
|
| Net revenues |
$597,879 |
$516,440 |
$449,607 |
$419,733 |
$383,598 |
| Cost of goods sold |
$289,709 |
$258,715 |
$222,307 |
$199,198 |
$185,722 |
|
|
|
|
|
|
| Gross profit |
$308,170 |
$257,725 |
$227,300 |
$220,535 |
$197,876 |
|
|
|
|
|
|
| Operating expenses: |
| R&D |
$ 23,859 |
$ 24,332 |
$ 23,884 |
$ 26,516 |
$ 19,994 |
| S, G & A |
$198,744 |
$163,116 |
$137,073 |
$121,351 |
$118,039 |
| Cost to equity |
- |
$225 |
$680 |
$406 |
- |
| In process R&D |
- |
$9,073 |
- |
- |
- |
| Arbitration and settlement income |
- |
$(5,700) |
$(26,350) |
- |
- |
|
|
|
|
|
|
| Total operating expenses |
$222,603 |
$187,438 |
$164,555 |
$122,197 |
$138,439 |
|
|
|
|
|
|
| Operating income |
$85,567 |
$70,287 |
$62,745 |
$98,338 |
$59,437 |
| Other income (expense), net |
$(565) |
$7,015 |
$9,591 |
$7,864 |
$(2) |
|
|
|
|
|
|
| Income before provision for income taxes |
$85,002 |
$77,302 |
$72,336 |
$106,202 |
$59,435 |
| Provision for income taxes |
$25,698 |
$25,322 |
$23,227 |
$37,806 |
$20,202 |
|
|
|
|
|
|
| Net income |
$59,304 |
$51,980 |
$49,109 |
$68,396 |
$39,233 |
|
|
|
|
|
|
| Income per share: |
| Basic |
$2.34 |
$2.01 |
$1.84 |
$2.58 |
$1.54 |
| Diluted |
$2.27 |
$1.94 |
$1.78 |
$2.49 |
$1.50 |
| Weighted average number of shares |
25,389 |
25,824 |
26,746 |
26,478 |
25,523 |
| Common stock equivalents |
784 |
922 |
903 |
996 |
622 |
|
|
|
|
|
|
| Weighted average number of common and common equivalent shares |
26,173 |
26,746 |
27,649 |
27,474 |
26,145 |
|
|
|
|
|
|
| |
| Financial and Statistical Data: |
|
|
|
|
|
|
| Working capital |
$289,530 |
$261,757 |
$321,654 |
$330,288 |
$255,689 |
|
|
|
|
|
|
| Current ratio |
4.1 |
3.7 |
4.9 |
4.7 |
3.9 |
| Property, plant and equipment, net |
$137,807 |
$116,484 |
$90,775 |
$75,266 |
$69,337 |
|
|
|
|
|
|
| Capital expenditures |
$56,379 |
$57,790 |
$40,438 |
$33,774 |
$17,530 |
| Depreciation and amortization |
$36,462 |
$31,197 |
$27,504 |
$25,150 |
$27,756 |
|
|
|
|
|
|
| Total assets |
$649,693 |
$608,950 |
$572,735 |
$546,543 |
$467,757 |
| Total debt |
$6,038 |
$12,363 |
$28,876 |
$39,153 |
$45,843 |
|
|
|
|
|
|
| Stockholders' equity |
$539,884 |
$494,188 |
$479,648 |
$441,650 |
$355,135 |
| Return on average equity |
11.47% |
10.67% |
10.67% |
17.34% |
12.50% |
| Debt as a % of stockholders' equity |
1.12% |
2.50% |
6.02% |
8.87% |
12.90% |
|
|
|
|
|
|
| Employees |
2,016 |
1,875 |
1,826 |
1,661 |
1,546 |
|
| Net revenues per employee |
$297 |
$276 |
$246 |
$254 |
$248 |
(a) Reflects the adjustment to convert our investment in Arryx, Inc. to
the equity method for periods prior to the acquisition.
|
|